Flagship Harbor Advisors LLC boosted its position in shares of AstraZeneca plc (NYSE:AZN) by 4.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,248 shares of the company’s stock after purchasing an additional 305 shares during the period. Flagship Harbor Advisors LLC’s holdings in AstraZeneca were worth $323,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Buckingham Capital Management Inc. grew its position in AstraZeneca by 113.2% in the 1st quarter. Buckingham Capital Management Inc. now owns 58,095 shares of the company’s stock valued at $2,349,000 after purchasing an additional 30,843 shares during the period. Amundi Pioneer Asset Management Inc. lifted its position in AstraZeneca by 18.5% in the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 1,288,720 shares of the company’s stock worth $52,103,000 after buying an additional 201,645 shares during the last quarter. Park National Corp OH lifted its position in AstraZeneca by 17.0% in the 2nd quarter. Park National Corp OH now owns 278,271 shares of the company’s stock worth $11,487,000 after buying an additional 40,391 shares during the last quarter. Private Trust Co. NA lifted its position in AstraZeneca by 7.1% in the 2nd quarter. Private Trust Co. NA now owns 9,886 shares of the company’s stock worth $408,000 after buying an additional 658 shares during the last quarter. Finally, Carroll Financial Associates Inc. lifted its position in AstraZeneca by 29.7% in the 2nd quarter. Carroll Financial Associates Inc. now owns 3,140 shares of the company’s stock worth $129,000 after buying an additional 719 shares during the last quarter. 17.52% of the stock is owned by hedge funds and other institutional investors.
Shares of AstraZeneca stock opened at $47.25 on Friday. The company has a quick ratio of 0.75, a current ratio of 0.95 and a debt-to-equity ratio of 1.19. The company has a market cap of $117.26 billion, a PE ratio of 27.31, a P/E/G ratio of 1.50 and a beta of 0.47. The business has a 50 day moving average of $44.10 and a 200 day moving average of $41.61. AstraZeneca plc has a 52 week low of $35.30 and a 52 week high of $47.31.
A number of analysts recently weighed in on AZN shares. DZ Bank downgraded AstraZeneca from a “hold” rating to a “sell” rating in a research report on Tuesday, September 3rd. HSBC reiterated a “sell” rating on shares of AstraZeneca in a research report on Thursday, October 17th. Zacks Investment Research downgraded AstraZeneca from a “strong-buy” rating to a “hold” rating and set a $49.00 price objective for the company. in a research report on Thursday, October 3rd. Argus boosted their price objective on AstraZeneca to $50.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Finally, ValuEngine downgraded AstraZeneca from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Four equities research analysts have rated the stock with a sell rating, five have given a hold rating and twelve have issued a buy rating to the company’s stock. AstraZeneca presently has a consensus rating of “Hold” and a consensus price target of $46.53.
In other AstraZeneca news, major shareholder Plc Astrazeneca bought 425,000 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The stock was bought at an average price of $19.00 per share, for a total transaction of $8,075,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Article: Average Daily Trade Volume – What You Need to Know
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.